Conducting an Early Phase Clinical Trial to Assess for HPV Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests the Potential for Clinical Benefits of HPV Patients
Phase: EARLY_PHASE1
Conditions: HPV Infection
Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Cover Page 
 
 
 
Release Date: May 5, 2025  
 
ClinicalTrials.gov ID: NCT06959563      
 
Unique Protocol ID: IND 169135   
 
Brief Title: Early Phase Clinical Trial About Therapeutic Biological Product Mix for 
Treating HPV (9vHPV-BCG)  
 
Official Title:
Conducting an Early Phase Clinical Trial to Assess for HPV Antigen Presentation 
Therapeutic Biological Product Mix Activity That Suggests the Potential for 
Clinical Benefits of HPV Patients. 
 
Secondary IDs:
IND 169135 [Registry ID: FDA, Investigational New Drug Application (IND)] 
NPI-1831468511 [Registry ID: HHS, Health Care Provider Individual] 
NPI-1023387701 [Registry ID: HHS, Health Care Provider Organization]  
FWA00015357 [Registry ID: HHS, Human Protections Administrator] 
IORG0007849 [Registry ID: HHS, IORG] 
IRB00009424 [Registry ID: HHS, IRB]  
 
Human APCs treat HPV antigen into small fragments, and then clear HPV in vivo.  
 

1 
 
6. Protocol [21 CFR 312.23(a)(6)]  
6a. Study protocol [21 CFR 312.23(a)(6)]  
 
Contents 
 
21 CFR§312.23 (a)(6) .......................................................................................................................... 2 
Protocols. ............................................................................................................................................. 2 
(i) 
A protocol for each planned study. (Protocols for studies not submitted initially in the IND should be 
submitted in accordance with § 312.30(a).) In general, protocols for Phase 1 studies may be less detailed 
and more flexible than protocols for Phase 2 and 3 studies. Phase 1 protocols should be directed primarily 
at providing an outline of the investigation - an estimate of the number of patients to be involved, a 
description of safety exclusions, and a description of the dosing plan including duration, dose, or method 
to be used in determining dose - and should specify in detail only those elements of the study that are 
critical to safety, such as necessary monitoring of vital signs and blood chemistries. Modifications of the 
experimental design of Phase 1 studies that do not affect critical safety assessments are required to be 
reported to FDA only in the annual report. ................................................................................................... 2 
(ii) 
In Phases 2 and 3, detailed protocols describing all aspects of the study should be submitted. A 
protocol for a Phase 2 or 3 investigation should be designed in such a way that, if the sponsor anticipates 
that some deviation from the study design may become necessary as the investigation progresses, 
alternatives or contingencies to provide for such deviation are built into the protocols at the outset. For 
example, a protocol for a controlled short-term study might include a plan for an early crossover of 
nonresponders to an alternative therapy. .................................................................................................... 4 
(iii) 
A protocol is required to contain the following, with the specific elements and detail of the 
protocol reflecting the above distinctions depending on the phase of study: ............................................. 5 
(a) 
A statement of the objectives and purpose of the study. .................................................................. 5 
(b) 
The name and address and a statement of the qualifications (curriculum vitae or other statement of 
qualifications) of each investigator, and the name of each sub-investigator (e.g., research fellow, resident) working 
under the supervision of the investigator; the name and address of the research facilities to be used; and the name 
and address of each reviewing Institutional Review Board. ............................................................................... 5 
(c) 
The criteria for patient selection and for exclusion of patients and an estimate of the number of 
patients to be studied. ................................................................................................................................ 9 
(d) 
A description of the design of the study, including the kind of control group to be used, if any, and a description 
of methods to be used to minimize bias on the part of subjects, investigators, and analysts. ................................ 9 
(e) 
The method for determining the dose(s) to be administered, the planned maximum dosage, and the 
duration of individual patient exposure to the drug. ................................................................................ 11 
(f) 
A description of the observations and measurements to be made to fulfill the objectives of the study. ....... 12 
(g) 
A description of clinical procedures, laboratory tests, or other measures to be taken to monitor the 
effects of the drug in human subjects and to minimize risk. ................................................................... 13 
 
 
It is my commitment that our Institutional Review Board (IRB) (IRB00009424) that complies with the 
requirements set forth in part 56 will be responsible for the initial and continuing review and approval of 
each of the studies in my proposed clinical investigation and that the sponsor-investigator (me i.e. Han Xu, 
M.D., Ph.D.) will report to our IRB (IRB00009424) the proposed changes in my research activity in accordance 
with the requirements of part 56.  
 
I write the statement with respect to each clinical study involving human subjects that it either will be 
conducted in compliance with the institutional review board regulations in part 56 or will not be subject to 
the regulations under §56.104 or §56.105; and that it either will be conducted in compliance with the 
informed consent regulations in part 50 or will not be subject to the regulations under §50.23 and §50.24.  
 

2 
 
21 CFR§312.23 (a)(6)  
Protocols.  
 
(i) A protocol for each planned study. (Protocols for studies not submitted initially in the IND should 
be submitted in accordance with § 312.30(a).) In general, protocols for Phase 1 studies may be 
less detailed and more flexible than protocols for Phase 2 and 3 studies. Phase 1 protocols should 
be directed primarily at providing an outline of the investigation - an estimate of the number of 
patients to be involved, a description of safety exclusions, and a description of the dosing plan 
including duration, dose, or method to be used in determining dose - and should specify in detail 
only those elements of the study that are critical to safety, such as necessary monitoring of vital 
signs and blood chemistries. Modifications of the experimental design of Phase 1 studies that do 
not affect critical safety assessments are required to be reported to FDA only in the annual report.  
 
The protocol for the planned IND 169135 Phase 1 clinical study NCT06959563:  
In general, protocols for Phase 1 studies may be less detailed and more flexible. Phase 1 protocol 
of the planned IND 169135 clinical study NCT06959563 will be directed primarily at providing an 
outline of the clinical investigation NCT06959563 as follows:  
 
 An estimate of the number of patients to be involved:  
 20 Cervical HPV Infection Patients  
 A description of participant inclusions:   
 Positive testing HPV by standard PCR assay  
 HPV infection without symptoms  
 No clinical signs indicative of oncology   
 TB negative participant is negative IGRA blood test with TB antigens.  
 A description of safety exclusions:   
 Pregnant 
 Thrombosis 
 Allergy  
 TB positive participant is positive IGRA blood test with TB antigens.  
 Symptoms of HPV infection.  
 Clinical signs suggestive of other infection  
 Symptoms suggestive of other infection  
 Clinical signs indicative of oncology   
 Evidence of critical illness  
 A description of the dosing plan:  
 Duration: 4-weeks = 28-days  
 Dose:  
 2 x Dose i.e., 2 x 0.5 mL = 1 mL 9vHPV Vaccine like as following:  
https://dailymed.nlm.nih.gov/dailymed/  
LABEL: GARDASIL 9 - human papillomavirus 9-valent vaccine, recombinant injection, 
suspension 
NDC 0006-4119-03 
BLA 125508 
Packager: Merck Sharp & Dohme LLC  
 Each 0.5-mL dose contains human papillomavirus L1 protein of each type 
adsorbed on amorphous aluminum hydroxyphosphate sulfate adjuvant as follows:  
Type 6 (30 mcg), Type 11 (40 mcg), Type 16 (60 mcg), Type 18 (40 mcg), Type 31 
(20 mcg), Type 33 (20 mcg), Type 45 (20 mcg), Type 52 (20 mcg), Type 58 (20 mcg). 
 GARDASIL 9 - Each 0.5-mL dose x 2 = 1 mL   

3 
 
 Before 5 minutes for the percutaneous route with the multiple puncture device, 
above biologic will be added into following biologic:   
 1 Dose i.e., 50 mg wet weight organism i.e., 1 Intact Vial of lyophilized powder like as 
following:  
https://dailymed.nlm.nih.gov/dailymed/  
LABEL: BCG VACCINE - bacillus calmette-guerin substrain tice live antigen injection, 
powder, lyophilized, for solution  
NDC 0052-0603-02  
BLA 103050  
Packager: Merck Sharp & Dohme Corp.  
Active Ingredient(s) and Strength(s) like as following:  
BCG VACCINE contains live bacteria. BCG VACCINE for percutaneous use is an 
attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain 
of Mycobacterium bovis. The TICE® strain used in this BCG VACCINE preparation. The TICE® 
BCG organism is grown for preparation of freeze-dried cake.  
 Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis  
 1 to 8 × 10^8 colony forming units (CFU) of BCG (equivalent to approximately 50 mg wet weight)  
 Merck TICE® BCG organism 50 MG wet weight  
 The method to be used in determining dose:  
 Purchased below FDA approved biological products according to labels:  
 2 x Dose i.e., 2 x 0.5 mL = 1 mL 9vHPV Vaccine like as following:  
https://dailymed.nlm.nih.gov/dailymed/  
LABEL: GARDASIL 9 - human papillomavirus 9-valent vaccine, recombinant injection, 
suspension  
NDC 0006-4119-03 
BLA 125508 
Packager: Merck Sharp & Dohme LLC    
 Before 5 minutes for the percutaneous route with the multiple puncture device, 
above biologic will be added into following biologic:  
 1 Dose i.e., 50 mg wet weight organism i.e., 1 Intact Vial of lyophilized powder like as 
following:  
https://dailymed.nlm.nih.gov/dailymed/  
LABEL: BCG VACCINE - bacillus calmette-guerin substrain tice live antigen injection, 
powder, lyophilized, for solution  
NDC 0052-0603-02  
BLA 103050  
Packager: Merck Sharp & Dohme Corp.  
 
 We will specify in detail only those elements of the IND 169135 Phase 1 clinical study 
NCT06959563 that are critical to safety, such as necessary monitoring of vital signs and 
blood chemistries.  
 The vital signs of safety exclusions:   
 Pregnant 
 Thrombosis 
 Allergy  
 TB positive participant is positive IGRA blood test with TB antigens.  
 Clinical signs indicative of oncology   
 Evidence of critical illness  
 Modifications of the experimental design of Phase 1 studies that do not affect critical safety 
assessments are required to be reported to FDA only in the annual report. 
 

4 
 
21 CFR § 312.30  
(a) New protocol. Whenever a sponsor intends to conduct a study that is not covered by a protocol 
already contained in the IND, the sponsor shall submit to FDA a protocol amendment containing 
the protocol for the study. Such study may begin provided two conditions are met:  
(1) The sponsor has submitted the protocol to FDA for its review; and  
(2) the protocol has been approved by the Institutional Review Board (IRB) with responsibility 
for review and approval of the study in accordance with the requirements of part 56. The 
sponsor may comply with these two conditions in either order. 
 
Phase 1 protocols will be directed primarily at providing an outline of the investigation: 
 An estimate of the number of patients to be involved:  
 20 Cervical HPV Infection Patients  
 A description of safety exclusions:  
 Pregnant 
 Thrombosis 
 Allergy  
 TB positive participant is positive IGRA blood test with TB antigens.  
 Symptoms of HPV infection.  
 Clinical signs suggestive of other infection   
 Symptoms suggestive of other infection   
 Clinical signs indicative of oncology   
 Evidence of critical illness  
 A description of the dosing plan for duration:  
 Our trial duration will be 4-week duration. 
 A description of the dosing plan for dose:  
 9vHPV Vaccine 1.0 mL plus BCG Vaccine 50 MG Mix  
 A description of the dosing plan for method to be used in determining dose:   
 LABEL: GARDASIL 9 - human papillomavirus 9-valent vaccine, recombinant injection, suspension  
NDC 0006-4119-03 
BLA 125508 
Packager: Merck Sharp & Dohme LLC     
 Before 5 minutes for the percutaneous route with the multiple puncture device, above 
biologic will be added into following biologic:  
 LABEL: BCG VACCINE - bacillus calmette-guerin substrain tice live antigen injection, powder, 
lyophilized, for solution  
NDC 0052-0603-02  
BLA 103050  
Packager: Merck Sharp & Dohme Corp.  
 
 The elements of the study that are critical to safety:  
 The necessary monitoring of vital signs:  
 TB positive participant is positive IGRA blood test with TB antigens.  
 Positive testing HPV by standard PCR assay  
 
(ii) In Phases 2 and 3, detailed protocols describing all aspects of the study should be submitted. 
A protocol for a Phase 2 or 3 investigation should be designed in such a way that, if the 
sponsor anticipates that some deviation from the study design may become necessary as 
the investigation progresses, alternatives or contingencies to provide for such deviation are 
built into the protocols at the outset. For example, a protocol for a controlled short-term 
study might include a plan for an early crossover of nonresponders to an alternative therapy.  
 
The IND 169135 Phase 1 clinical study need not describe Phases 2 and 3 protocols.  
 

5 
 
(iii) A protocol is required to contain the following, with the specific elements and detail of the 
protocol reflecting the above distinctions depending on the phase of study:  
 
(a) A statement of the objectives and purpose of the study.  
 
1. Treat Infection of Multiple HPV Virus Strains.  
2. Activate human HPV Antigen Presentation Reaction.  
3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into 
small peptide fragments, and then clear HPV virus in vivo.  
 
Statement 
 
The objectives and purpose of the IND 169135 Phase 1 clinical study will be 2 doses of the biological product, 
9vHPV VACCINE add into 1 dose of the biological product, BCG VACCINE and mix above them before 5 
minutes to take the percutaneous use and treat the Infection of Multiple HPV Virus Strains.   
 
(b) The name and address and a statement of the qualifications (curriculum vitae or other statement of 
qualifications) of each investigator, and the name of each sub-investigator (e.g., research fellow, 
resident) working under the supervision of the investigator; the name and address of the research 
facilities to be used; and the name and address of each reviewing Institutional Review Board.  
 
Contact Person: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medical Director  
Contact Company: Medicine Invention Design Incorporation  
Contact Address: 5545 Burnside Drive, Rockville, MD 20853, USA  
Contact Call: 001-301-222-7143  
Contact Fax: 001-866-458-0099  
Contact Email: hanxumdphd@midinc.us  
 
The name of investigator:  
 Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medical Director  
Health Care Provider - Individual (NPI - 1831468511)  
The address of investigator: (Online Clinical Trial Site)  
 5545 Burnside Drive, Rockville, MD 20853, USA  
The statement of the qualifications of investigator:  
21 CFR 312.53(c)(1) 
A signed investigator statement (Form FDA-1572) containing:  
(i) The name and address of the investigator:  
 The name of the investigator:  
 Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medical Director 
 The address of the investigator: (Online Clinical Trial Site)  
 5545 Burnside Drive, Rockville, MD 20853, USA 
(ii) The name and code number, if any, of the protocol(s) in the IND identifying the 
study(ies) to be conducted by the investigator:  
 Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medical Director  
 Health Care Provider - Individual (NPI - 1831468511)  
 Health Care Provider - Health Maintenance Organization (Code - 302R00000X)   
 IND Number: IND 169135 
 ClinicalTrials.gov ID: NCT06959563  
(iii) The name and address of any medical school, hospital, or other research facility where 
the clinical investigation(s) will be conducted:  
 The name of research facility:  
 Medicine Invention Design Incorporation  
 Medicine Invention Design Incorporation (FWA00015357)  
 Medicine Invention Design Incorporation (IORG0007849)  
 Health Care Provider - Group/Organization (NPI - 1023387701)  
 Health Care Provider - Health Maintenance Organization (Code - 302R00000X)  
 Health Care Provider - Research Clinic/Center (Code - 261QR1100X)  

6 
 
 The address of research facility: (Online Clinical Trial Site)  
 5545 Burnside Drive, Rockville, MD 20853, USA  
(iv) The name and address of any clinical laboratory facilities to be used in the study:  
 The name of clinical laboratory facility:  
 Medicine Invention Design Incorporation  
 Medicine Invention Design Incorporation (FWA00015357)  
 Medicine Invention Design Incorporation (IORG0007849)  
 Health Care Provider - Clinical Medical Laboratory (Code - 291U00000X)  
 The address of clinical laboratory facility: (Online Clinical Trial Site)  
 5545 Burnside Drive, Rockville, MD 20853, USA  
(v) The name and address of the IRB that is responsible for review and approval of the study(ies):   
 The name of the IRB:  
 Medicine Invention Design Incorporation (MIDI) IRB #1 (IRB00009424) 
 The address of the IRB: (Online Clinical Trial Site)  
 5545 Burnside Drive, Rockville, MD 20853, USA  
(vi) A commitment by the investigator that he or she:  
(a) Will conduct the study(ies) in accordance with the relevant, current protocol(s) and 
will only make changes in a protocol after notifying the sponsor, except when 
necessary to protect the safety, the rights, or welfare of subjects;  
(b) Will comply with all requirements regarding the obligations of clinical 
investigators and all other pertinent requirements in this part;  
(c) Will personally conduct or supervise the described investigation(s);  
(d) Will inform any potential subjects that the drugs are being used for investigational purposes 
and will ensure that the requirements relating to obtaining informed consent (21 CFR 
part 50) and institutional review board review and approval (21 CFR part 56) are met;  
(e) Will report to the sponsor adverse experiences that occur in the course of the 
investigation(s) in accordance with § 312.64;  
(f) Has read and understands the information in the investigator's brochure, including 
the potential risks and side effects of the drug; and  
21 CFR 312.55(a) 
Before the investigation begins, a sponsor (other than a sponsor-investigator) shall 
give each participating clinical investigator an investigator brochure containing the 
information described in § 312.23(a)(5). 
(g) Will ensure that all associates, colleagues, and employees assisting in the conduct 
of the study(ies) are informed about their obligations in meeting the above commitments.  
 
Commitment 
 
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator 
 
A commitment by the sponsor-investigator that I:  
(a) Will conduct the study (NCT06959563) in accordance with the relevant, current 
protocol(s) and will only make changes in a protocol after notifying the sponsor, 
except when necessary to protect the safety, the rights, or welfare of subjects.  
(b) Will comply with all requirements regarding the obligations of clinical investigators 
and all other pertinent requirements in this part.  
(c) Will personally conduct or supervise the described investigation(s).   
(d) Will inform any potential subjects that the drugs are being used for investigational 
purposes and will ensure that the requirements relating to obtaining informed consent (21 
CFR part 50) and institutional review board review and approval (21 CFR part 56) are met;  
(e) Will report to the sponsor (Han Xu, M.D. Ph.D., FAPCR) adverse experiences that 
occur in the course of the investigation(s) in accordance with § 312.64.   

7 
 
(f) Have read and understands the information in the investigator's brochure, including 
the potential risks and side effects of the drug.   
21 CFR 312.55(a) 
Han Xu, Sponsor-Investigator, need not give an investigator brochure containing the 
information described in § 312.23(a)(5). 
(g) Will ensure that all associates, colleagues, and employees assisting in the conduct of the 
study (NCT06959563) are informed about their obligations in meeting the above commitments.  
 
(vii) A commitment by the investigator that, for an investigation subject to an institutional review 
requirement under part 56, an IRB that complies with the requirements of that part will be 
responsible for the initial and continuing review and approval of the clinical investigation and that 
the investigator will promptly report to the IRB all changes in the research activity and all 
unanticipated problems involving risks to human subjects or others, and will not make any 
changes in the research without IRB approval, except where necessary to eliminate 
apparent immediate hazards to the human subjects.  
 
Commitment 
 
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medical Director  
 
It is my commitment that our Institutional Review Board (IRB) (IRB00009424) that complies 
with the requirements set forth in part 56 will be responsible for the initial and continuing 
review and approval of each of the studies in my proposed clinical investigation and that the 
sponsor-investigator (me i.e. Han Xu, M.D., Ph.D.) will report to our IRB (IRB00009424) the 
proposed changes in my research activity in accordance with the requirements of part 56.  
 
(viii) A list of the names of the sub-investigators (e.g., research fellows, residents) who 
will be assisting the investigator in the conduct of the investigation(s).  
 
Not available right now  
 
The name of the research facility:  
 Medicine Invention Design Incorporation (MIDI)  
 Medicine Invention Design Incorporation (FWA00015357)  
 Medicine Invention Design Incorporation (IORG0007849)  
 Health Care Provider - Group/Organization (NPI - 1023387701)  
 Health Care Provider - Research Clinic/Center (Code - 261QR1100X)  
The address of the research facility: (Virtual / Mobile / Online)  
 5545 Burnside Drive, Rockville, MD 20853, USA  
 
The name of Institutional Review Board:  
 Medicine Invention Design Incorporation (MIDI) IRB #1 (IRB00009424) 
 Health Care Provider - Individual (NPI 1831468511)  
 Health Care Provider - Clinical Ethicist (Code - 174V00000X)  
The address of Institutional Review Board: (Virtual / Mobile / Online)  
 5545 Burnside Drive, Rockville, MD 20853, USA  
 
21 CFR 312.53(c)(2) 
Curriculum vitae. A curriculum vitae or other statement of qualifications of the investigator 
showing the education, training, and experience that qualifies the investigator as an expert in 
the clinical investigation of the drug for the use under investigation.  
 
The statement of the qualifications of sponsor-investigator:  
The education, training, and experience that qualifies the sponsor-investigator as an 
expert in the IND 169135 Phase 1 clinical investigation of FDA approved biological products 
for the use under the IND 169135 Phase 1 clinical investigation:  
 

8 
 
The information about medical and scientific training of sponsor-investigator (SI) 
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, IORG Director 
 
The information about medical and scientific experience of sponsor-investigator (SI)  
 Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, IORG Director  
 1980-1986 - M.D., Ph.D. accepted by NIH; Beijing Medical University School of Basic Medical Science; 
Beijing, China  
Dr. Han Xu received clinical education and clinical training in 1980-1986.  
 1986-1995 - Principal Investigator (PI), Clinical Attending Physician, Beijing Clinical Research Institute, 
Beijing Friendship Hospital; Beijing, China  
Dr. Han Xu received clinical training and had clinical experience in 1986-1995.  
 1995-2000 - M.D., Ph.D. accepted by NIH; Visiting Scholar, NCI-Frederick, National Cancer Institute 
(NCI), National Institutes of Health (NIH); Frederick, Maryland  
Dr. Han Xu received clinical investigator training in 1995-2000  
 2000-2006 - Principal Investigator (PI) / Program Director (PD), Pharm1 Incorporation - Beijing Office; 
Beijing, China  
 2006 - Sponsor-Investigator (SI) / IRB Chair (Study Chair, SC) / IORG Director (Study Director, SD) / 
Medical Monitor (MM) / Safety Officer (SO), Medicine Invention Design Incorporation (MIDI); 
Rockville, Maryland   
 2013 - Director Member, Medicine Invention Design Incorporation (MIDI) (IORG0007849) - Institution or 
Organization (IORG) of Registration at U.S. Department of Health and Human Services (HHS)  
 2013 - Board Member and Chair, Medicine Invention Design Incorporation (MIDI) IRB #1 (IRB00009424) - 
Institutional Review Board (IRB) of Registration at U.S. Department of Health and Human Services (HHS)  
Dr. Han Xu had already been Sponsor-Investigator (SI) approved by IRB00009424.  
 2020 - Active Member, Fellow of the APCR (FAPCR), Academy of Physicians in Clinical Research (APCR) 
- APCR Membership Eligibility - Physician Investigator  
 Certificate of Fellow of Academy of Physicians in Clinical Research (FAPCR)  
 Academy of Physicians in Clinical Research (APCR)  
 PI (Principal Investigator) in clinical trials  
 Medical Director of Clinical Research Site  
 2023 - FDA Pre-Assignment - My IND has been granted. My pre-assigned number is 169135.  
 Individual Sponsor: HAN XU  
 Organization Sponsor: Medicine Invention Design Incorporation  
 2023 update - ClinicalTrials.gov ID: NCT06959563 under 42 CFR Part 11  
 Responsible Party (Sponsor-Investigator)  
 Study Principal Investigator [Principal Investigator (PI)]  
 Study Director (Medical Director)  
 Study Chair (IRB Chair)  
 
INSTITUTION / UNIVERSITY  
DEGREE / 
TRAINING  
Start Date 
MM/YYYY 
End Date 
MM/YYYY 
FIELD OF STUDY 
Beijing Medical University (BMU)  
School of Basic Medical Sciences (SBMS)  
B.S. 
0719/86  
 
Basic and Clinical 
Medicines  
Beijing Medical University (BMU)  
School of Basic Medical Sciences (SBMS)  
Department of Medicine  
Internship 
09/1984 
08/1985 
Clinical Medicines  
Beijing Medical University (BMU)  
School of Basic Medical Sciences (SBMS) 
Internship 
09/1985 
07/1986 
Basic Medicines  
Beijing Friendship Hospital (BFH)   
Beijing Clinical Research Institute (BCRI)  
Residency 
Physician  
07/1986  
06/1991  
Internal Medicine   
NIH-NCI accepted my degree obtained in BMU 
like as USA equivalent doctorate titles  
M.D.  
Ph.D.  
07/1986  
 
Basic and Clinical 
Medicines  
National Institutes of Health (NIH)  
National Cancer Institute (NCI)  
Visiting 
Scholar  
12/1995  
03/2000 
Basic and Clinical 
Research  

9 
 
 The qualifications of sponsor-investigator:  
 Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, Medical Director, IRB Chair  
 NPI 1831468511 - Individual  
 Clinical Ethicist - (Code - 174V00000X)  
 Specialist Research Study - (Code - 1744R1102X)  
 ClinicalTrials.gov ID: NCT06959563 [Responsible Party (Sponsor-Investigator)]  
 FWA00015357 (Human Protections Administrator)  
 Medicine Invention Design Incorporation (MIDI) (IORG0007849)  
 Medicine Invention Design Incorporation (MIDI) IRB #1 (IRB00009424)  
 Federal-wide Assurance (FWA) for the Protection of Human Subjects (FWA00015357)  
 NPI 1023387701 - Organization  
 Research Clinic/Center - (Code - 261QR1100X)  
 Clinic/Center Health Services - (Code - 261QH0100X)  
 Clinic/Center Multi-Specialty - (Code - 261QM1300X)  
 Clinic/Center Medical Specialty - (Code - 261QM2500X)  
 Clinical Medical Laboratory - (Code - 291U00000X)  
 Health Maintenance Organization - (Code - 302R00000X)  
 Pharmacy Mail Order Pharmacy - (Code - 3336M0002X)  
 
(c) The criteria for patient selection and for exclusion of patients and an estimate of the 
number of patients to be studied. 
 
The criteria for patient selection:  
 Cervical HPV Infection Patients  
 Positive testing HPV by standard PCR assay  
 HPV infection without symptoms  
 No clinical signs indicative of oncology   
 TB negative participant is negative IGRA blood test with TB antigens.  
 
The criteria for patient exclusion: 
 Pregnant 
 Thrombosis  
 Allergy  
 TB positive participant is positive IGRA blood test with TB antigens.  
 Symptoms of HPV infection.  
 Clinical signs suggestive of other infection  
 Symptoms suggestive of other infection.  
 Clinical signs indicative of oncology  
 Evidence of critical illness  
 
(d) A description of the design of the study, including the kind of control group to be used, if any, 
and a description of methods to be used to minimize bias on the part of subjects, investigators, 
and analysts.  
 
 Study Type: Interventional  
 Primary Purpose: Treatment 
 Study Phase: Phase 1 Clinical Trial  
 Interventional Study Model: Single Group Assignment / Single Usage / Single Dosage 
 Number of Arms: 1 / single-arm study  
 Masking: None (Open Label) 
 Allocation: N/A 
 Enrollment:  

10 
 
 20 Cervical HPV Infection Patients  
 Positive testing HPV by standard PCR assay  
 HPV infection without symptoms  
 No clinical signs indicative of oncology   
 TB negative participant is negative IGRA blood test with TB antigens.  
 Dose: 9vHPV Vaccine 1.0 mL plus BCG Vaccine 50 MG Mix  
 2 x Dose i.e., 2 x 0.5 mL = 1 mL 9vHPV Vaccine like as following:  
https://dailymed.nlm.nih.gov/dailymed/ 
LABEL: GARDASIL 9 - human papillomavirus 9-valent vaccine, recombinant injection, 
suspension  
NDC 0006-4119-03 
BLA 125508 
Packager: Merck Sharp & Dohme LLC   
 Before 5 minutes for the percutaneous route with the multiple puncture device, above 
biologic will be added into following biologic:  
 1 Dose i.e., 50 mg wet weight organism i.e., 1 Intact Vial of lyophilized powder like 
as following:  
https://dailymed.nlm.nih.gov/dailymed/  
LABEL: BCG VACCINE - bacillus calmette-guerin substrain tice live antigen injection, 
powder, lyophilized, for solution  
NDC 0052-0603-02  
BLA 103050  
Packager: Merck Sharp & Dohme Corp.  
 Route: Percutaneous Use with Multiple Puncture Device  
 Duration: Our trial duration will be 4-week duration.  
 Endpoint: Negative testing HPV by standard PCR assay after percutaneous use 21 days.  
 
The methods to be used to minimize bias on the part of subjects, investigators, and analysts:  
21 CFR 312.53(c)(1) 
(vi) A commitment by the investigator that he or she:  
(a) Will conduct the study(ies) in accordance with the relevant, current protocol(s) 
and will only make changes in a protocol after notifying the sponsor, except when 
necessary to protect the safety, the rights, or welfare of subjects;  
(b) Will comply with all requirements regarding the obligations of clinical 
investigators and all other pertinent requirements in this part;  
(c) Will personally conduct or supervise the described investigation(s);  
(d) Will inform any potential subjects that the drugs are being used for 
investigational purposes and will ensure that the requirements relating to 
obtaining informed consent (21 CFR part 50) and institutional review board 
review and approval (21 CFR part 56) are met;  
(e) Will report to the sponsor adverse experiences that occur in the course of the 
investigation(s) in accordance with § 312.64;  
(f) Has read and understands the information in the investigator's brochure, 
including the potential risks and side effects of the drug; and  
21 CFR 312.55(a) 
Before the investigation begins, a sponsor (other than a sponsor-investigator) 
shall give each participating clinical investigator an investigator brochure 
containing the information described in § 312.23(a)(5). 
(g) Will ensure that all associates, colleagues, and employees assisting in the 
conduct of the study(ies) are informed about their obligations in meeting the above 
commitments.  
 

11 
 
Commitment 
 
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator 
 
A commitment by the sponsor-investigator that I:  
(a) Will conduct the study (IND 169135) in accordance with the relevant, current 
protocol(s) and will only make changes in a protocol after notifying the sponsor, 
except when necessary to protect the safety, the rights, or welfare of subjects.  
(b) Will comply with all requirements regarding the obligations of clinical investigators 
and all other pertinent requirements in this part.  
(c) Will personally conduct or supervise the described investigation(s).   
(d) Will inform any potential subjects that the drugs are being used for investigational 
purposes and will ensure that the requirements relating to obtaining informed consent (21 
CFR part 50) and institutional review board review and approval (21 CFR part 56) are met;  
(e) Will report to the sponsor (Han Xu, M.D. Ph.D., FAPCR) adverse experiences that 
occur in the course of the investigation(s) in accordance with § 312.64.   
(f) Have read and understands the information in the investigator's brochure, 
including the potential risks and side effects of the drug.   
21 CFR 312.55(a) 
Han Xu, Sponsor-Investigator, need not give an investigator brochure containing the 
information described in § 312.23(a)(5). 
(g) Will ensure that all associates, colleagues, and employees assisting in the conduct 
of the clinical study (IND 169135) are informed about their obligations in meeting the 
above commitments.  
 
21 CFR 312.53(c)(1) 
(vii) A commitment by the investigator that, for an investigation subject to an institutional 
review requirement under part 56, an IRB that complies with the requirements of that part will 
be responsible for the initial and continuing review and approval of the clinical investigation 
and that the investigator will promptly report to the IRB all changes in the research activity 
and all unanticipated problems involving risks to human subjects or others, and will not make 
any changes in the research without IRB approval, except where necessary to eliminate 
apparent immediate hazards to the human subjects.  
 
Commitment 
 
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator 
 
It is my commitment that our Institutional Review Board (IRB) (IRB00009424) that 
complies with the requirements set forth in part 56 will be responsible for the initial 
and continuing review and approval of each of the studies in my proposed clinical 
investigation and that the sponsor-investigator (me i.e. Han Xu, M.D., Ph.D.) will 
report to our IRB (IRB00009424) the proposed changes in my research activity in 
accordance with the requirements of part 56.  
 
(e) The method for determining the dose(s) to be administered, the planned maximum dosage, 
and the duration of individual patient exposure to the drug.  
 
 The method for determining the single dose to be administered:  
 2 x Dose i.e., 2 x 0.5 mL = 1 mL 9vHPV Vaccine like as following:  
https://dailymed.nlm.nih.gov/dailymed/ 
LABEL: GARDASIL 9 - human papillomavirus 9-valent vaccine, recombinant injection, 
suspension  
NDC 0006-4119-03 
BLA 125508 
Packager: Merck Sharp & Dohme LLC   

12 
 
 Before 5 minutes for the percutaneous route with the multiple puncture device, 
above biologic will be added into following biologic:  
 1 Dose i.e., 50 mg wet weight organism i.e., 1 Intact Vial of lyophilized powder 
like as following:  
https://dailymed.nlm.nih.gov/dailymed/  
LABEL: BCG VACCINE - bacillus calmette-guerin substrain tice live antigen injection, 
powder, lyophilized, for solution  
NDC 0052-0603-02  
BLA 103050  
Packager: Merck Sharp & Dohme Corp.  
 
 The planned maximum dosage: 
 2 x Dose i.e., 2 x 0.5 mL = 1 mL 9vHPV Vaccine like as following:  
https://dailymed.nlm.nih.gov/dailymed/ 
LABEL: GARDASIL 9 - human papillomavirus 9-valent vaccine, recombinant injection, 
suspension  
NDC 0006-4119-03 
BLA 125508 
Packager: Merck Sharp & Dohme LLC  
Active Ingredient(s) and Strength(s) like as following:  
 Each 0.5-mL dose contains human papillomavirus L1 protein of each type adsorbed on 
amorphous aluminum hydroxyphosphate sulfate adjuvant as follows:  
Type 6 (30 mcg), Type 11 (40 mcg), Type 16 (60 mcg), Type 18 (40 mcg), Type 31 (20 
mcg), Type 33 (20 mcg), Type 45 (20 mcg), Type 52 (20 mcg), Type 58 (20 mcg). 
 GARDASIL 9 - Each 0.5-mL dose x 2 = 1 mL    
 Before 5 minutes for the percutaneous route with the multiple puncture device, 
above biologic will be added into following biologic:  
 1 Dose i.e., 50 mg wet weight organism i.e., 1 Intact Vial of lyophilized powder 
like as following:  
https://dailymed.nlm.nih.gov/dailymed/  
LABEL: BCG VACCINE - bacillus calmette-guerin substrain tice live antigen 
injection, powder, lyophilized, for solution  
NDC 0052-0603-02  
BLA 103050  
Packager: Merck Sharp & Dohme Corp.  
Active Ingredient(s) and Strength(s) like as following:  
BCG VACCINE contains live bacteria. BCG VACCINE for percutaneous use is 
an attenuated, live culture preparation of the Bacillus of Calmette and Guerin 
(BCG) strain of Mycobacterium bovis. The TICE® strain used in this BCG 
VACCINE preparation. The TICE® BCG organism is grown for preparation of 
freeze-dried cake.  
 Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis  
 1 to 8 × 10^8 colony forming units (CFU) of BCG (equivalent to approximately 
50 mg wet weight)  
 Merck TICE® BCG organism 50 MG wet weight  
 
 The duration of individual patient exposure to the drug: 4-weeks = 28-days 
 
 Duration: Our trial duration will be 4-week duration.  
 
(f) A description of the observations and measurements to be made to fulfill the objectives of the study.  
 

13 
 
 The observations and measurements to be made to fulfill the objectives of the study:  
 Positive testing HPV by standard PCR assay before the study.  
 TB negative participant is negative IGRA blood test with TB antigens before the study.  
 Negative testing HPV by standard PCR assay after 21 days of dosage  
 HPV protein derivative will be positive with 1/10 Dose of 9vHPV Vaccine by IGRA 
blood test to take the IGRA blood test with 9vHPV antigens after the percutaneous 
use 3 weeks of the biological product mix dosage.  
 
 Endpoint: Negative testing HPV by standard PCR assay after percutaneous use 21 days.  
 
(g) A description of clinical procedures, laboratory tests, or other measures to be taken to 
monitor the effects of the drug in human subjects and to minimize risk.  
 
 Negative testing HPV by standard PCR assay after percutaneous use 21 days.   
 BCG should not be given to individuals previously infected with M. tuberculosis. A person 
will give the IGRA blood test with TB antigens. TB positive participant is positive IGRA 
blood test with TB antigens.  
 BCG can activate the human antigen presenting cells (APCs) to treat HPV virus target 
protein antigen into small peptide fragments and to clear HPV virus antigens in vivo. So, 
the related allergen in vivo will decrease gradually.  
 
The clinical procedures, laboratory tests, or other measures to be taken to monitor the 
effects of the biological product mix in human subjects and to minimize risk like as follows:  
 
 The clinical procedures to be taken to minimize risk: 
 To take the percutaneous use can minimize risk.  
 2 doses of the biological product, 9vHPV VACCINE add into 1 dose of the biological product, 
BCG VACCINE and mix above them before 5 minutes to take the percutaneous use.  
 BCG can activate the human antigen presenting cells (APCs) to treat HPV virus target 
protein antigen into small peptide fragments and to clear HPV virus antigens in vivo. 
So, the related allergen in vivo will decrease gradually.  
 
 The clinical and laboratory tests to be taken to monitor the effects of the biological 
product mix in human subjects:  
 Positive testing HPV by standard PCR assay before the study. 
 Negative testing HPV by standard PCR assay after 21 days of dosage   
 HPV protein derivative will be positive with 1/10 Dose 9vHPV Vaccine by the IGRA 
blood test to take the IGRA blood test with 9vHPV antigens after the percutaneous 
use 3 weeks of the biological product mix dosage.  
 
 The clinical and laboratory tests to be taken to minimize risk:  
 The risk exclusions like as following:   
 Pregnant 
 Thrombosis 
 Allergy  
 TB positive participant is positive IGRA blood test with TB antigens.  
 Symptoms of HPV infection   
 Clinical signs suggestive of other infection   
 Symptoms suggestive of other infection   
 Clinical signs indicative of oncology   
 Evidence of critical illness  
 

14 
 
21 CFR 312.10(a) 
A sponsor may request FDA to waive applicable requirement under this part. A waiver request may 
be submitted either in an IND or in an information amendment to an IND.  
[21 CFR 312.10(a)(3)]  
Other information justifying a waiver.  
 
According to 21 CFR 312.10(a), the sponsor (Han Xu, M.D., Ph.D., FAPCR) needs to request FDA to 
waive applicable requirement under this part which means 21 CFR Part 312. Therefore, my 
investigation must waive the requirements of 21 CFR 312.53(c). In particular, my investigation must 
waive the requirements of 21 CFR 312.53(c)(1). Also, my clinical investigation must waive the 
requirements of 21 CFR §312.305 (c)(1) and 21 CFR §312.305 (c)(3). Although I am not a licensed 
physician, I still can be a qualified sponsor-investigator for my IND Phase I clinical investigation. 
 
21 CFR 312.53(c)(1)(vi)(d) 
Will inform any potential subjects that the drugs are being used for investigational purposes and 
will ensure that the requirements relating to obtaining informed consent (21 CFR part 50) and 
institutional review board review and approval (21 CFR part 56) are met; 
 
I write the statement with respect to each clinical study involving human subjects that it either will be 
conducted in compliance with the institutional review board regulations in part 56 or will not be subject to 
the regulations under §56.104 or §56.105; and that it either will be conducted in compliance with the 
informed consent regulations in part 50 or will not be subject to the regulations under §50.23 and §50.24.  
 
21 CFR 312.53(c)(1)(vii)  
A commitment by the investigator that, for an investigation subject to an institutional review 
requirement under part 56, an IRB that complies with the requirements of that part will be 
responsible for the initial and continuing review and approval of the clinical investigation and that 
the investigator will promptly report to the IRB all changes in the research activity and all 
unanticipated problems involving risks to human subjects or others, and will not make any changes 
in the research without IRB approval, except where necessary to eliminate apparent immediate 
hazards to the human subjects. 
 
It is my commitment that our Institutional Review Board (IRB) (IRB00009424) that complies with 
the requirements set forth in part 56 will be responsible for the initial and continuing review and 
approval of each of the studies in my proposed clinical investigation and that the sponsor-
investigator (me i.e. Han Xu, M.D., Ph.D.) will report to our IRB (IRB00009424) the proposed changes 
in my research activity in accordance with the requirements of part 56.  
 
To minimize potential bias resulting from orally verbal voice administration of assessments, the 
sponsor (Han Xu, M.D., Ph.D., FAPCR) will consider using automated virtual interviewers to 
administer the assessments remotely. According to similar principles, the formal pre-IND review will 
be conducted in the format -- written response only (WRO) by email. 
 
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, Medical Director 
Health Care Provider - Individual (NPI - 1831468511)  
Medicine Invention Design Incorporation (MIDI) IRB #1 (IRB00009424)  
Health Care Provider - Group/Organization (NPI - 1023387701)  
Mail: 5545 Burnside Drive, Rockville, MD 20853  
Call: 301-222-7143  
Fax: 866-458-0099  
E-mail: hanxumdphd@midinc.us